[Edaily Reporter NA EUN-KYUNG ] #Aimed Bio Inc., a company specializing in antibody-drug conjugates (ADCs), announced on the 12th that it recorded consolidated revenue of 28.7 billion won and operating profit of 4.6 billion won for the first half of this year.

Second-quarter revenue reached 20.2 billion won, a 166% increase compared to the same period last year (7.6 billion won). Cumulative revenue for the first half of the year more than tripled compared to the same period last year, and the company has posted four consecutive half-year operating profits from the second half of 2024 through the first half of 2026.

These results are significant as they indicate that global technology transfer agreements have begun to translate into revenue in earnest. The results reflect milestone payments related to the development progress of the ADC candidate “ODS025,” which was licensed to Boehringer Ingelheim of Germany, as well as joint development costs associated with “AMB303,” which is being co-developed with SK Plasma.

ADCs are next-generation anticancer drugs that combine cytotoxic drugs with antibodies to selectively deliver the drugs to cancer cells. As they can enhance therapeutic efficacy while reducing damage to healthy tissue compared to existing anticancer drugs, this field is considered a hotspot for investment and technology transfers by global pharmaceutical companies. Recently, the value of individual candidate compounds that have entered the clinical stage has been assessed more highly than that of simple platforms, leading to a trend of expanding technology transfer deals.

“ODS025,” Aimed Bio Inc.’s flagship pipeline, is an ADC candidate currently in development for various solid tumors. Having recently received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), the company plans to commence global clinical trials at 13 institutions across five countries, including the United States and South Korea. This clinical trial, which aims to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE), will involve approximately 90 patients.

Another pipeline candidate, “AMB303,” is an ADC candidate that targets ROR1. ROR1 is a protein known to be expressed in various solid tumors, including lung, breast, and ovarian cancers, and the company is working toward entering clinical trials within the year through a joint development effort with SK Plasma.

The company is establishing a business structure that secures a stable cash flow based on upfront payments from technology transfer agreements, R&D funding, and milestone payments at each development stage, while reinvesting these funds into the development of its own pipeline. The company also emphasizes that, unlike many biotech startups that continue to operate at a loss due to the burden of R&D expenses, it maintains an operating profit based on revenue from technology transfers.

Aimed Bio Inc. plans to expand the proportion of in-house clinical development based on its established financial foundation. The company explained that its net assets, including cash and cash equivalents, currently exceed 200 billion won. Building on this, the company intends to directly develop its subsequent ADC pipeline to the clinical stage and pursue a strategy that combines technology licensing with in-house development.

Heo Nam-gu, CEO of Aimed Bio Inc., stated, “Based on the success of our technology transfers, we have established a financial foundation that allows us to expand our in-house clinical development, with net assets—including cash and cash equivalents—exceeding 200 billion won.” He added, “We will continue to invest in bringing our subsequent ADC pipeline directly into the clinical phase to further strengthen our growth foundation.”